Shilpa Medicare has gained 7% to Rs 488 on the BSE in early morning trade after the company said that it has received Establishment Inspection Report (EIR) from the US drug regulator for its formulation manufacturing facility in Telangana following the audit in November last year.
“The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Shilpa Medicare Ltd's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017,” Shipla Medicare on Saturday, March 16, 2018, said in a regulatory filing.
FDA has
“The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Shilpa Medicare Ltd's formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017,” Shipla Medicare on Saturday, March 16, 2018, said in a regulatory filing.
FDA has